Neovascular Age Related Macular Degeneration Clinical Trial
Official title:
The Effect of Intravitreal Bevacizumab & Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration
One concern about repeated intravitreal injections of bevacizumab (Avastin) and ranibizumab
(Lucentis) in wet age related macular degeneration, is that in addition to blocking the
proteins that triggers the development and proliferation of abnormal vessels in the center
of the retina, they may also result in changes in the normal vessels that feeds the outer
part of the retina.
Small vessels with fenestrations (such as those that feed the outer part of the retina,
which are called choriocapillaris) appear to be especially sensitive to this protein (called
vascular endothelial growth factor, VEGF) withdrawal.
It is estimated that global blood flow in the vascular layer under the retina (called
choroid) may be indirectly assessed by measuring the amplitude of the ocular pulsation (the
pressure inside the eye change according to the cardiac cycle, similar to the change in
blood pressure) which is called Ocular Pulse Amplitude (OPA). The Pascal Dynamic Contour
Tonometer (Pascal DCT) is a new tonometer (a device which measures the pressure within the
eye) designed to measure intraocular pressure and ocular pulse amplitude.
No published study has yet assessed the effect of bevacizumab (Avastin) or ranibizumab
(Lucentis) treatment for wet AMD (or on any other retinal disease) on OPA. This is our aim
in this pilot study, in which we will measure the pressure within the eye just prior to
bevacizumab/Ranibizumab treatment, followed by repeated measurements a week and a month
after the treatment.
For this purpose, up to 60 patients with wet AMD will be recruited.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02251366 -
NVAMD Satellite Study
|
N/A | |
| Unknown status |
NCT00767949 -
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT00764738 -
Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
|
Phase 2/Phase 3 | |
| Completed |
NCT00383370 -
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
|
Phase 1 | |
| Completed |
NCT01678963 -
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT03930641 -
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT01863199 -
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
|
Phase 4 | |
| Recruiting |
NCT05562947 -
A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT04239027 -
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT00574093 -
Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
|
Phase 2 | |
| Completed |
NCT00685100 -
Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone
|
Phase 3 | |
| Completed |
NCT01942213 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.
|
N/A |